<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10</volume><submitter>Venturini L</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Most cancers maintain telomeres by activating telomerase but a significant minority, mainly of mesenchymal origin, utilize an alternative lengthening of telomeres (ALT) mechanism.&lt;h4>Methods&lt;/h4>In this study we comparatively analyzed the prognostic relevance of ALT in a monoinstitutional series of 85 liposarcoma patients as a function of the marker (ALT-associated promyelocytic leukemia bodies (APB) versus heterogeneous telomeres) used to classify the tumor.&lt;h4>Results&lt;/h4>Independently of the detection approach, ALT proved to be a prognostic discriminant of increased mortality, although the prognostic relevance of the two markers appeared at different follow-up intervals (at 10 years for APB and 15 years for telomeres).&lt;h4>Conclusions&lt;/h4>Overall, we confirmed ALT as a</pubmed_abstract><journal>BMC cancer</journal><pagination>254</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2894794</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis.</pubmed_title><pmcid>PMC2894794</pmcid><pubmed_authors>Motta R</pubmed_authors><pubmed_authors>Venturini L</pubmed_authors><pubmed_authors>Gronchi A</pubmed_authors><pubmed_authors>Daidone M</pubmed_authors><pubmed_authors>Zaffaroni N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis.</name><description>&lt;h4>Background&lt;/h4>Most cancers maintain telomeres by activating telomerase but a significant minority, mainly of mesenchymal origin, utilize an alternative lengthening of telomeres (ALT) mechanism.&lt;h4>Methods&lt;/h4>In this study we comparatively analyzed the prognostic relevance of ALT in a monoinstitutional series of 85 liposarcoma patients as a function of the marker (ALT-associated promyelocytic leukemia bodies (APB) versus heterogeneous telomeres) used to classify the tumor.&lt;h4>Results&lt;/h4>Independently of the detection approach, ALT proved to be a prognostic discriminant of increased mortality, although the prognostic relevance of the two markers appeared at different follow-up intervals (at 10 years for APB and 15 years for telomeres).&lt;h4>Conclusions&lt;/h4>Overall, we confirmed ALT as a</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 Jun</publication><modification>2025-04-19T09:51:57.127Z</modification><creation>2019-03-27T00:32:00Z</creation></dates><accession>S-EPMC2894794</accession><cross_references><pubmed>20525266</pubmed><doi>10.1186/1471-2407-10-254</doi></cross_references></HashMap>